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Abstract Parathyroid hormone (PTH) plays a critical role
in calcium and phosphorus metabolism. Interestingly, in two
forms of hyperparathyroidism (excessive amount of PTH in
the serum), the metabolic disturbances in patients with
chronic kidney disease (CKD) significantly differ from those
with primary hyperparathyroidism (PHP). Since an intuitive
understanding of these PTH-linked regulatory mechanisms
are hardly possible, we developed a mathematical model
using clinical data (1586 CKD and 40 PHP patients). The
model was composed of a set of ordinary differential equa-
tions, in which the regulatory mechanism of PTH together
with other key factors such as 1,25-Dihydroxyvitamin D
(1,25(OH)2D) and calcium was described in the tissues
including bone, the kidney, the serum, and the parathyroid
glands. In this model, an increase in PTH was induced by its
autonomous production in PHP, while PTH in CKD was
elevated by a decrease in feedback inhibition of 1,25(OH)2D
in the serum, as well as an increase in stimulation by phos-
phorus in the serum. The model-based analysis revealed
characteristic differences in the outcomes of hyperparathy-
roidism in CKD and PHP. The calcium exchange in bone, for
instance, was predicted significantly higher in PHP than
CKD. Furthermore, we evaluated the observed and predicted
responses to the administration of calcimimetics, a recently
developed synthetic drug that modulated efficacy of cal-
cium-sensing receptors. The results herein support the notion
that the described model would enable us to pose testable
hypotheses about the actions of PTH, providing a quantita-
tive analytical tool for evaluating treatment strategies of PHP
and CKD.
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Introduction
The physiological system that regulates the balances of
calcium and phosphorus in our body comprises a large
number of regulatory components as well as a complex
network of molecular and cellular interactions [1]. Since
simple, logical reasoning is seldom possible, building
mathematical models and conducting computational simu-
lations are often useful to our understanding of a mechanism
of actions of key regulatory factors. We have previously
developed two versions of mathematical models for calcium
and phosphorus metabolism, focusing on the role of para-
thyroid hormone (PTH) and 1,25(OH)2D with and without
inclusion of the role of FGF23 [1, 2]. These models were able
to explain the transient alterations in the concentrations of
calcium in the serum and the urine by considering a rapid
exchangeable pool of calcium (*100 mmol). However, the
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previous models did not take into account a potential varia-
tion in the secretory mass of the parathyroid glands or the
balance of calcium and phosphorus in bone. An inclusion of
bone remodeling in the model increases the exchangeable
amount of calcium approximately by 300-fold. Thus, the
existing models were not suited for interpreting some of the
clinical data that presented abnormality in the secretion of
PTH or bone metabolism.
The study herein aimed to develop a refined mathe-
matical model that would be capable of simulating the
alterations in the parathyroid glands and bone remodeling.
In particular, we focused on two forms of hyperparathy-
roidism in which the amount of PTH in the serum was
anomalously elevated. One of such disorders was chronic
kidney disease (CKD), while the other was primary
hyperparathyroidism (PHP). These two forms of hyper-
parathyroidism result from unrelated causes for the eleva-
tion of PTH, and the symptoms of these patients differ. The
described model was validated as to whether it would be
able to correctly predict each of the characteristic responses
in calcium and phosphorus metabolism in the serum and
the urine. Since the total amounts of calcium and phos-
phorus are considered in this extended model, it is possible
to evaluate both transient and chronic responses.
In formulating mathematical expressions, we employed
observable state variables such as glomerular filtration
rates (GFRs), the serum concentrations of PTH,
1,25(OH)2D, calcium, and phosphorus, and the urinary
excretions of calcium and phosphorus. Besides the calcium
and phosphorus balances in the serum and the urine, we
also included two sub-compartments corresponding to the
parathyroid glands and bone (bone forming osteoblasts and
bone degrading osteoclasts). The rates of growth and
degradation as well as the functional status of these com-
partments were subject to the regulatory factors (e.g., PTH,
1,25(OH)2D, calcium, and phosphorus) [3–7]. In inter-
preting clinical data, we used the procedure taken by Parfitt
and co-workers [8–13]. We did not include the data for
FGF23, bone mineral density, or bone mineral content
because of their limited availability.
The specific aim of the current study was to build a
mathematical model for calcium and phosphate metabolism,
focusing on the regulatory roles of PTH and 1,25(OH)2D.
The predictive model was then applied to the two forms of
hyperparathyroidism (CKD and PHP) and the concentra-
tions of calcium and phosphate in the serum and the urine
were evaluated. Furthermore, we examined potential effects
of the administration of calcimimetics to patients with
hyperparathyroidism. Calcimimetics is a recently developed
class of drugs, which is considered to modulate the action of
calcium-sensing receptors [14, 15]. These calcium-sensing
receptors are located not only in the parathyroid gland but
also in the intestine and the kidney tubule [16]. We
hypothesized that potential therapeutic strategies differ to
patients with CKD and PHP because of the regulatory
mechanisms for the induction of hyperparathyroidism.
Through the examination of the predicted outcomes in
response to calcimimetics, we investigated a possible con-
tribution of the calcium-sensing receptors located in the
parathyroid glands, the intestine, and the kidney tubule.
Materials and methods
Clinical data from the patients with CKD
The use of the archived and the collected data obeyed a
study protocol, which was approved by the review boards
of each of the institutions. Using the laboratory procedures
described previously [2], the following data were obtained
from a pool of 1586 CKD patients with stable renal func-
tion: GFR measured by the creatinine clearance; the serum
concentrations of PTH, 1,25(OH)2D, calcium, and phos-
phorus; and the urinary output of calcium and phosphorus.
Note that GFR was obtained from the calculation of the
24 h creatinine clearance, since its estimates with a sta-
tistical formula cannot be used to compute fractional
excretions. The obtained values of the creatinine clearances
were normalized to 1.73 m2 of the body surface area using
the Mosteller formula [17]. Calcium and phosphorus
excretions were measured in 24 h urine samples (mg/24 h).
They were expressed as the ratios of calcium and phos-
phorus clearances, respectively, to creatinine clearance,
which were independent of urinary volume. Each patient
was represented by a single set of values collected on
the same morning, and the urine collections were started on
the previous morning. Regarding medications, 4% of the
patients were having calcium supplements and patients on
vitamin D or cinacalcet were excluded from the analysis.
Clinical data from the patients with PHP
Retrospective data of 40 consecutive patients (33 females
and 7 males) with a mean age at diagnosis of
55.6 ± 2.9 years, who had surgery for PHP were collected.
Most patients had an asymptomatic form of this disease
and were followed in the same hospital for a mean period
of 390 ± 95 days before surgery and up to 6 months after
surgery. During this period, clinical and laboratory data
were obtained from the patients’ records. No patient was
submitted to treatment with calcimimetics (including cin-
acalcet). The patients with GFRs lower than 60 ml/min
were excluded to rule out a possibility of secondary
hyperparathyroidism. For each patient, we obtained the
serum concentrations of PTH, 1,25(OH)2D, calcium, and
phosphorus. Whenever possible, we also collected data for
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the 24 h urinary excretions of calcium and phosphorus
together with GFR (evaluated with the Cockcroft–Gault
formula). Since the values for ionized (free) calcium were
available for a limited number of the patients, we used the
amount of total calcium in the mathematical model. Note
that the amount of ionized calcium is assumed to be
approximately half of the total calcium.
Data processing
To characterize the relationships among clinical data, we
examined any correlations between a pair of measured
variables such as GFR and 1,25(OH)2D. For each pair, one
variable was chosen as an independent (driving) variable,
which was sorted in the ascending order and smoothed out
with a sliding average using 3–5 consecutive values (CKD
data) and 10 consecutive values (PHP data) [18]. Further-
more, outliers were removed using the procedure described
previously [19]. Using SPSS 16.0 software, the processed
data were partitioned into frequency bins, and the means
and their standard errors were calculated. Consequently,
the raw clinical data were converted into a list of mean
values and standard errors of the mean in each of the fre-
quency bins. Note that in CKD and PHP data processing,
GFR and the concentrations of PTH in the serum were used
as the chief driving variables, respectively.
Systems diagram with compartments
With reference to the systems diagram with varying com-
partments (Fig. 1), we included 4 additional compartments
to 11 original compartments in the previous model. The
original compartments were: 4 compartments in the serum
(calcium pool—[Qs(Ca)], phosphate pool—[Qs(P)], PTH—
[Qs(PTH)], and 1,25(OH)2D—[Qs(D)]); 2 compartments in
bone (calcium pool—[Qb(Ca)], and phosphorus pool—
[Qb(P)]); and 5 compartments in other tissues (intracellular
phosphate pool—[Qc(P)], 1a-hydroxylase in the kidney—
[Qk(E)], 1,25(OH)2D-dependent intestinal calcium trans-
porter—[Qi(TCa)], external balance-dependent phosphate
kidney transporter—[Qk(TP)], and secretory mass of the
parathyroid gland (QPT(C))] [1, 2].
In the present study, 4 additional compartments were
considered. They were 2 compartments in the parathyroid
glands ([QPT(sec)], and [QPT(qui)]); and 2 compartments in
bone (bone-forming osteoblast cells [Qob], and bone-
degrading osteoclast cells [Qoc]). First, two compartments
in the parathyroid glands enabled us to describe long-term
perturbations of calcium and phosphate homeostasis clo-
sely linked to hyperparathyroidism. Second, the inclusion
of 2 bone-related compartments allowed us to evaluating
calcium and phosphorus homeostasis through bone
remodeling in a relatively long time scale (in the order of
1 month to years) as well as a more rapid exchange of
calcium and phosphorus (in the order of 1 h).
Mathematical formulation
The rates of change of the above pools were equated to the
algebraic sum of the corresponding inward and outward
fluxes. Mathematical expressions are shown in Appendix.
We considered three kinetic models such as a linear-dif-
fusional model, a Michaelis–Menten model, and a hyper-
bolic tangent model. Here are some examples. First, the
linear-diffusional model was used to approximate a passive
calcium transport process in the intestine. Second, the
Michaelis–Menten model was employed to simulate a
feedback inhibition process of the synthesis of
1,25(OH)2D. Third, the hyperbolic tangent function was,
for instance, applied to model inhibition of a PTH release
by calcium in the serum.
Numerical simulation
The model was encoded in the Madonna language (Uni-
versity of California, Berkeley), and the computations were
conducted in three modules: the differential equation
module describing dynamical behaviors of the compart-
ments; the auxiliary equation module defining the fluxes
into and out of the compartments, and the reference state
module providing the initial steady-state values of the
dynamical variables using the parameter values listed in
Table 1. These parameter values were derived based on
existing data as well as heuristic parameter fitting [1]. A
perturbation to a specific state variable was introduced
around a steady-state reference, and the dynamical system
responses were evaluated. The source codes will be made
available upon request.
To simulate the action of calcimimetics, we referred to the
study published previously [20]. The affinity of calcium to
the calcium-sensing receptor as well as the amount of PTH
secretion were estimated using clinical PTH data, and the
predicted effects of calcimimetics on each of the three
locations of the calcium-sensing receptors (i.e., parathyroid
glands, intestine, and kidney tubule) were evaluated. Note
that in this simulation a potential effect of calcimimetics on
the proliferation of parathyroid gland cells was not included.
Results
Analysis of clinical data from the patients with CKD
and PHP
The data from the patients with CKD exhibited a clear
correlation of the selected variables to GFR (Fig. 2).
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Among six variables, two variables (concentrations of
1,25(OH)2D and calcium in the serum) showed a positive
correlation to GFR. Four other variables (concentrations of
PTH and phosphorus in the serum, and the excreted frac-
tion of calcium and phosphorus in the urine) presented a
negative correlation to GFR. Small deviations from the
observed trends were detected in the calcium concentration
in the serum at a normal GFR (Fig. 2c) as well as the
urinary excretion of phosphorus at a low GFR (Fig. 2f).
The similar data analysis was conducted for the patients
with PHP using the level of PTH in the serum as an
independent variable (Fig. 3). Data showed a clear ten-
dency in which an increase in PTH elevated the calcium
level in the serum, while it reduced the phosphorus level in
the serum. Both the secretions of calcium and phosphorus
in the urine were increased together with an elevation of
PTH. Although these two sets of data in CKD and PHP
patients presented an excess amount of PTH, the mecha-
nism for PTH elevation was apparently different.
Evaluation of calcium balances in the patients
with CKD and PHP
Using the mathematical model with the data from the
patients with CKD and PHP, we next evaluated calcium
balance as a function of PTH concentration in the serum
(Fig. 4). The external and internal balances are depicted in
Fig. 4a and b, respectively, based on the calcium
exchanges through the urinary output and bone remodel-
ing. The results demonstrated that at the same concen-
tration of PTH in the serum, the calcium exchanges
through the kidney and bone were significantly higher in
the patients with PHP than those with CKD. The com-
parison between CKD and PHP also indicated that an
increase in the PTH level in the serum reduced the
fractional content of calcium in bone severer in PHP than
CKD (Fig. 4c).
As a potential cause for these differences, we examined
a potential role of affinity of a PTH receptor in the calcium
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level in bone (Fig. 4d). A higher affinity significantly
decreased the fractional content of calcium in bone, sug-
gesting that the observed differences could result from
differential affinities of PTH to bone in CKD and PHP,
although other regulatory mechanisms would also be
possible.
Table 1 Values of the
parameters and the reference
states
Ob osteoblast, Oc osteoclast,
VD 1,25(OH)2 Vitamin D, PT
parathyroid gland
Symbol Remark Value
Qob0 Total number of Ob 3.36 9 10
8 (–)
Qoc0 Total number of Oc 0.1 9 Qob0 (–)
Joc0 Rate of Oc production 2.0 9 10
5 (1/h)
Job0 Rate of Ob production 2.0 9 10
6 (1/h)
Kb(Ca) Fraction of Ca turnover in bone 0.1 (1/year)
Job(Ca)R Ca flux (dependent on Ob) 2.5 (mM)
Joc(Ca)R Ca flux (dependent on Oc) 35 (pg/ml)
Joc(Ca)S Ca flux sensitivity (dependent on Oc) 0.05 (pg/ml)
-1
Qb(Ca)0 Ca pool in bone 3.25 9 10
4 (mmol)
Fract Fraction of secreting PT cells 0.2 (–)
kact Rate of PT cell activation 0.03 (1/h)
kmult0 Rate of PT cell multiplication ([Ca, P, VD]-dependent) 0.03 (–)
Kmult(Ca)R Ca affinity (inhibiting PT cell growth) 2.4 (mM)
kmult(Ca)S Ca sensitivity (inhibiting PT cell growth) 1.2 (1/mM)
kmult(D)R VD affinity (inhibiting PT cell growth) 190 (pg/ml)
kmult(D)S VD sensitivity (inhibiting of PT cell growth) 0.03 (1/pg/ml)
kmult(P)R P affinity (stimulating PT cell growth) 1.55 (mM)
QPT Lim Max. number PT cells can grow 10 (–)
Rob–oc Ratio of Ob/Oc pools 10 (–)
kmult(P)S P sensitivity (stimulating PT cell growth) 1 (1/mM)
QPT0 Total number of PT cells 1.0 9 10
8 (–)
Joc(Ca)-PTH0 Normalized Ca flux (dependent on Oc) 1 (–)
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Fig. 2 Analysis of the clinical
data of the patients with CKD as
a function of GFR. The open
circles represent the mean value
in the frequency bins, while the
solid line indicates the modeling
results. Note that N is the
number of data points. a PTH
concentration in the serum
(N = 607). b 1,25(OH)2D
concentration in the serum
(N = 206). c Calcium
concentration in the serum
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Predicted outcomes in response to the administration
of a calcimimetic
Using the described model, we next examined the effects in
response to the administration of calcimimetics (Fig. 5).
Note that calcimimetics, i.e., type II calcium receptor
agonists, work as allosteric modulators, and they require
the presence of calcium to activate the receptor. The
observed and simulated data for CKD and PHP are shown
(Fig. 5). Note that the condition ‘‘PT’’ represents the pre-
dicted outcomes of calcimimetics that was effective only in
the parathyroid cells, while the condition ‘‘PT–I–K’’ des-
ignates the predicted outcomes effective in the parathyroid
cells, the intestine, and the kidney.
In the simulation for the patients with CKD (Fig. 5a),
the major effect in ‘‘PT’’ was the alteration in the PTH
concentration in the serum with a slight increase in the
phosphorus concentration. In ‘‘PT–I–K’’ where calcimi-
metics was effective to the calcium-sensing receptors in the
parathyroid cells, the intestine, and the kidney, we
observed a smaller reduction of the PTH concentration and
a markedly increase in the urinary excretion of calcium
together with a reduction in the calcium concentration in
the serum.
Regarding the predictions for the patients with PHP
(Fig. 5b), under ‘‘PT’’ in which calcimimetics was effec-
tive only in the parathyroid glands, the fractional fall in the
PTH concentration in the serum was smaller than the
predictions for CKD. When the effects of calcimimetics on
the intestine and the kidney were included in ‘‘PT–I–K’’,
the alteration of the PTH concentration was smaller than
that for CKD with a substantial increase in the urinary
excretion of calcium and a small fall in the serum calcium.
Lastly, a long-term simulation for a period of 12 years
was conducted for a hypothetical CKD patient, who pre-
sented a low GFR (initially 20% of a normal value).
Although the residual GFR was maintained at the initial
20% level after a renal failure, the PTH concentration in
the serum continually rose chiefly because the functional
mass of the parathyroid glands gradually increased. When
calcimimetics was administered in 10 years after the renal
failure, the model predicted a sudden, substantial fall in the
PTH concentration in the serum followed by its gradual
elevation.
Discussion
We described the extended mathematical model for ana-
lyzing calcium and phosphorus metabolism. Two major
extensions from the previous models were the refinement
of the states of the parathyroid glands, and the inclusion of
a large pool of calcium and phosphorus involved in bone
remodeling. The former allowed us to evaluate the role of
PTH in metabolic disorders such as PHP, while the latter
enabled to predict the chronic responses in CKD (in the
order of 1 month to years) including the extended pool of
calcium in bone. With these new features in the extended
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model, we examined the role of PTH in calcium and
phosphorus homeostasis using the clinical data from the
patients with CKD and PHP. In both forms of hyperpara-
thyroidism, the level of PTH in the serum was simulated
with the distinctively different mechanism of its elevation.
The present study revealed a number of aspects that
distinguished the hyperparathyroidism of CKD and of PHP.
First, the most striking difference was that the calcium
turnover was significantly higher in PHP than CKD. Our
prediction is consistent with clinical data showing that a
turnover ratio of calcium in bone is 0.006 per year for CKD
and 0.13 per year for PHP. Second, several feedback loops
regulating the levels of 1,25(OH)2D, calcium, and phos-
phorus in the serum were dynamically affecting the level of
PTH in CKD, but the elevated PTH level in the serum in
PHP was not primarily resulted from those feedback sig-
nals. Instead, those loops oppositely functioned so as to
suppress hyperparathyroidism but virtually no effective
outcome was observed. Third, in the computational simu-
lation for evaluating the responses to the administration of
calcimimetics, the predicted therapeutic outcomes were
markedly different in the two forms of hyperparathyroid-
ism (CKD and PHP). Our simulation results indicated that
the major effect of calcimimetics might be targeted to the
calcium-sensing receptor in the parathyroid glands. These
observations, possibly deduced in the past on an intuitive
basis, were quantitatively validated through the described
model-based analysis. Although basic molecular interac-
tions are included in the described mathematical model, it
does not completely represent complex, physiological
phenomena in mineral metabolism. The predicted respon-
ses to the administration of calcimimetics present a testable
hypothesis, which can be examined in pre-clinical studies.
Note that the difference in the sample numbers in CKD and
PHP is due to the different prevalence of those disorders
and availability of patients. Additional clinical data in PHP
should be useful to interpret the described model-based
predictions.
Because of the complex functional structure, any
mathematical model might be regarded as a simplification
of the system that regulates the balances of calcium and
phosphorus in the human body. For instance, we presented
another version of the model that included a feedback loop
representing the controlled secretion of FGF23, a phos-
phaturic hormone [21]. FGF23 was formulated to lower the
renal threshold for phosphorus, inhibit the production of
1,25(OH)2D in the kidney as well as the production of
PTH. In the current study we did not encode the molecular
mechanisms involved in the action of FGF23 or bone
mineralization [22], since clinical epidemiological data
were not available.
PTH has multiple functions in our body, and bone is a
highly dynamic structure in which structural and functional
differences exist in cortical and trabecular bones. In this
article we identified quantifiable state variables related to
hyperparathyroidism, and evaluated the clinically relevant
aspects of calcium and phosphorus metabolism treating
bone as a single entity. The predictions from the described
model as well as further analysis regarding the role of
FGF23 in the two forms of hyperparathyroidism and
inclusion of more detailed features in bone remodeling [23]
should warrant our better understanding of hyperparathy-
roidism and development of therapeutic strategies for CKD
and PHP.
In conclusion, hyperparathyroidism is an excess
amount of PTH in the serum that causes various health
problems including kidney diseases, osteoporosis, and
joint disorders. The described model provides a mathe-
matical framework for predicting and evaluating effects of
potential therapeutic agents prior to and during clinical
trials. It contributes to a fundamental understanding of
physiology of hyperparathyroidism as well as calcium and
phosphate metabolism in bone and the kidney. A further
evaluation of the role of PTH in concert to FGF23 is
needed to translate the current basic knowledge to clinical
practice.
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Appendix
Rate changes of the pools
In the described mathematical model, six differential
equations regarding the parathyroid glands and bone
remodeling were added to the original model (1):
d Qobð Þ=dt ¼ Job  kob  Qob
proliferation and degradation of osteoblastsð Þ ð1Þ
d Qocð Þ=dt ¼ Joc  koc  Qoc
proliferation and degradation of osteoclastsð Þ ð2Þ
d QbcðCaÞ
 
=dt ¼ JobðCaÞ  JocðCaÞ
calcium pool in boneð Þ ð3Þ
d QbcðPÞ
 
=dt ¼ b JobðCaÞ  JocðCaÞ
 
ðphosphorus pool in bone;
b ¼ 5=3 in hydroxyapatiteÞ
ð4Þ
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d QPTðactÞ
 
=dt ¼ kact  QPTðinactÞ  kinact  QPTðactÞ
pool of secreting parathyroid gland cellsð Þ ð5Þ
d QPTðinactÞ
 
=dt¼ kinact QPTðactÞ þ kmult  kact  kapo
 
QPTðinactÞ pool of non - secreting parathyroid gland cellsð Þ
ð6Þ
Modeling of bone remodeling and the parathyroid
glands
Osteoblasts and osteoclasts were assumed to be produced
(Job, Joc) and degraded (kobQob, kocQoc) at known rates
(kob, koc), respectively (4). The osteoblast and osteoclast
activities are represented by their ability to store (Job(Ca)) or
mobilize (Joc(Ca)) calcium per cell. We assumed that the
osteoclast activity was stimulated by PTH following a
hyperbolic tangent model.
The cells of the parathyroid glands were assumed to be
in two functional states corresponding to two pools: non-
dividing, secreting cells (QPT(sec)), and potentially dividing
or quiescent cells, (QPT(qui)). A continuous interchange
between the two pools as well as a continuous rate of
production of quiescent cells was assumed. Furthermore,
we included a continuous rate of cell death (kapo) under the
inhibition of the serum calcium and 1,25(OH)2D as well as
the stimulation of the serum phosphorus (5–10). The con-
version rates between active and inactive as well as the
multiplication and death rates of the parathyroid cells can
be written as fluxes:
JPTðsecÞ ¼ kact  QPTðquiÞ  kinact  QPTðsecÞ ð7Þ
JPTðquiÞ ¼ kinact  QPTðsecÞ þ kmult  kact  kapo
   QPTðquiÞ
ð8Þ
JPTðmultÞ ¼ kmult  QPTðquiÞ  QPT R ð9Þ
JPTðapoÞ ¼ kapo  QPTðquiÞ  QPT R ð10Þ
The factor QPT_R, the fraction of the parathyroid cell
pool capable of dividing, was introduced since the size of
the parathyroid glands tends to a limit (15).
QPT ¼ QPTðsecÞ þ QPTðquiÞ ð11Þ
QPT R ¼ QPTM  QPTð Þ=QPTM ð12Þ
QPTM ¼ QPTLim  QPT0 ð13Þ
The functional dependence of the multiplication rates of
the parathyroid cells on the serum calcium and
1,25(OH)2D (kmult(D), kmult(Ca)) were assumed to be
decreasing sigmoid functions while the dependence on
the serum phosphorus (kmult(P)) is assumed to be an
increasing sigmoid function.
MultðDÞ0¼ 1 tanh kmultðDÞS  CsðDHÞ0 kmultðDÞR
   N D
ð14Þ
D Mult ¼ 1=MultðDÞ0 ð15Þ
MultðDÞ ¼ 1  tanh kmultðDÞS  CsðDHÞ  kmultðDÞR
   N D
ð16Þ
kmultðDÞ ¼ D Mult  MultðDÞ ð17Þ
MultðCaÞ0¼ 1 tanh kmultðCaÞS  CsðCaÞ0kmultðCaÞR
   N Ca
ð18Þ
Ca Mult ¼ 1=MultðCaÞ0 ð19Þ
MultðCaÞ ¼ 1 tanh kmultðCaÞS  CsðCaÞ  kmultðCaÞR
   N Ca
ð20Þ
kmultðCaÞ0 ¼ Ca Mult  MultðCaÞ0 ð21Þ
kmultðCaÞ ¼ Ca Mult  MultðCaÞ ð22Þ
MultðPÞ0 ¼ 1 þ tanh kmultðPÞS  CsðPÞ0  kmultðPÞR
   N P
ð23Þ
P Mult ¼ 1=MultðPÞ0 ð24Þ
MultðPÞ ¼ 1 þ tanh kmultðPÞS  CsðPÞ  kmultðPÞR
   N P
ð25Þ
kmultðPÞ0 ¼ P Mult  MultðPÞ0 ð26Þ
kmultðPÞ ¼ P Mult  MultðPÞ ð27Þ
The multiplication rate of inactive cells (kmult) was
given a reference value of kmult0 multiplied by the function
(kmult(DCaP)) equal to 1 in the reference state and which is
the sum of three components, respectively, dependent on
the serum concentrations of calcium (aCakmult(Ca)),
1,25(OH)2D (aDkmult(D)), and phosphorus (aPkmult(P))
multiplied by their weighting coefficients, respectively,
aCa, aD, and aP (assumed to be 1/3).
kmultðDCaPÞ0 ¼ aD  kmultðDÞ0 þ aCa  kmultðCaÞ0 þ aP
 kmultðPÞ0 ð28Þ
kmultðDCaPÞ ¼ aD  kmultðDÞ þ aCa  kmultðCaÞ þ aP  kmultðPÞ
ð29Þ
kmult ¼ kmult0  kmultðDCaPÞ ð30Þ
The bone cells, actively involved in the movements of
calcium, are constantly produced (Job and Joc) and removed
(Joc_Dec) at rates koc and kob defined by the equations:
koc ¼ Joc0=Qoc0 ð31Þ
kob ¼ Job=Qob0 ð32Þ
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Joc Dec ¼ koc  Qoc ð33Þ
As a first approximation the rate of production of
osteoblasts is assumed to be constant (Job).
Osteoblasts and osteoclasts are assumed to be respon-
sible for the bone deposition and removal of calcium,
respectively. The osteoblast-dependent calcium deposi-
tion (Job_(Ca)) depends on the size of the pool of osteo-
blast (Qob) and on the flux per osteoblast (Job(Ca)_Cas)
which depends on the serum concentration of calcium
(Job_(Ca)_Casf) assumed to obey Michaelis–Menten kinetics.
JobðCaÞ kO0 ¼ KbðCaÞ  QbðCaÞ0 ð34Þ
JobðCaÞ Casf 0 ¼ CsðCaÞ0= CsðCaÞ0 þ JbðCaÞ CasR
  ð35Þ
JobðCaÞ CasM ¼ JobðCaÞ0=JobðCaÞ Casf 0 ð36Þ
kob Ca ¼ JobðCaÞ kO0=Qob0 ð37Þ
Job ðCaÞ Casf ¼ CsðCaÞ= CsðCaÞ þ Job ðCaÞ CasR
  ð38Þ
JobðCaÞ Cas ¼ JobðCaÞ CasM  JobðCaÞ Casf ð39Þ
Job ðCaÞ ¼ kobðCaÞ  JobðCaÞ Cas  Qob ð40Þ
The osteoclast-dependent calcium mobilization (Joc(Ca)) is a
function of the size of the osteoclast pool (Qoc) and is a function
of the serum concentration of PTH (Joc(Ca)-PTHf). Rob–oc is the
ratio between the osteoclast and the osteoblast pools.
Joc Cað ÞPTHf0 ¼ 1 þ tanh
Joc Cað ÞPTHS  Cs PTHð Þ0  Joc Cað ÞPTHR
   ð41Þ
Joc Cað ÞPTHM ¼ Joc Cað ÞPTH0= Joc Cað ÞPTHf0  QbðCaÞ0
 
ð42Þ
Joc Cað ÞPTHf ¼ 1 þ tanh
Joc Cað ÞPTHS  CsðPTHÞ  Joc Cað ÞPTHR
   ð43Þ
Joc Cað ÞPTH ¼ Joc Cað ÞPTHM  Joc Cað ÞPTHf  QbðCaÞ ð44Þ
KocðCaÞ ¼ Roboc  KobðCaÞ ð45Þ
JocðCaÞ ¼ KocðCaÞ  Joc Cað ÞPTH  Qoc ð46Þ
QbðPÞ0 ¼ b  QbðCaÞ0 ð47Þ
Jb Cað ÞOS ¼ JobðCaÞ þ JocðCaÞ ð48Þ
Jb Pð ÞOS ¼ b  Jb Cað ÞOS ð49Þ
The kidney functional mass, reduced by a pathological
process as in CKD, is assumed to be proportional to the
glomerular filtration rate.
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